28 January 2025

Can a drug for glaucoma revolutionize the treatment of androgenetic alopecia?

An important publication in Postępy Biochemii sheds light on the potential use of latanoprost acid in the treatment of androgenetic alopecia, a condition targeted by our research at BioResearch Pharma. The inspiration for this exploration stems from the discovery that latanoprost, a widely used glaucoma medication, stimulates eyelash growth.

This observation initiated an in-depth analysis of the compound’s broader applications. Studies have demonstrated that after six months of treatment with latanoprost acid, hair parameters significantly improve. Leveraging BioResearch Pharma’s drug repurposing strategy, this therapy could reach the market faster, minimizing financial and technological risks while accelerating patient access to innovative solutions.

Androgenetic alopecia remains one of the most prevalent dermatological conditions.

Explore the full publication in the link:

Contact us

    *Required field
    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.